Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000

被引:87
作者
Bowles, SK
Lee, W
Simor, AE
Vearncombe, M
Loeb, M
Tamblyn, S
Fearon, M
Li, Y
McGeer, A
机构
[1] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada
[2] Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pharm, Toronto, ON, Canada
[3] Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Microbiol, Toronto, ON, Canada
[4] Hamilton Hlth Sci Corp, Dept Microbiol, Hamilton, ON, Canada
[5] Perth District Hlth Unit, Stratford, ON, Canada
[6] Ontario Publ Hlth Lab, Toronto, ON, Canada
[7] Natl Microbiol Lab Hlth Canada, Winnipeg, MB, Canada
关键词
oseltamivir; nursing home; influenza outbreak;
D O I
10.1046/j.1532-5415.2002.50153.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To describe the experience of Ontario long-term care facilities that used oseltamivir during influenza outbreaks in 1999/2000. DESIGN: Case series. SETTING: Ten Ontario long-term care facilities for older people and their residents. PARTICIPANTS: Older residents of long-term care facilities. INTERVENTION: Oseltamivir for treatment or prophylaxis during 11 influenza outbreaks in 1999/2000. MEASUREMENTS: Control of outbreaks; pneumonia, hospitalization, and death complicating acute influenza. RESULTS: All outbreaks were due to influenza A//H3N2/ Sydney/05/97. One facility elected to use oseltamivir for treatment and amantadine for prophylaxis. The remaining nine facilities (10 outbreaks) recommended oseltamivir for treatment and prophylaxis (after amantadine failure in five and as primary prophylaxis in five). Use of oseltamivir was associated with termination of the outbreak in all eight evaluable outbreaks. Overall, 178/185 (96%) case-residents met the case definition of influenza and had complete data for evaluation. Of these, 63 35%) were treated with antibiotics, 37 (21%) were diagnosed with pneumonia, 19 (11%) were hospitalized, and 16 (9%) died. Compared with residents receiving no therapy or who became ill while taking amantadine, residents who received oseltamivir within 48 hours of the onset of symptoms were less likely to be prescribed antibiotics, to be hospitalized, or to die (P <.05 for each outcome). These differences persisted and remained statistically significant when corrected for influenza immunization status. A total of 730 residents received oseltamivir prophylaxis for a median of 9 days (range 5-12). Of these, side effects were identified in 30 (4.1%), the most common being diarrhea (12 residents, 1.6%), cough (5, 0.7%), confusion (4, 0.5%) and nausea (4,0.5%). CONCLUSIONS: Oseltamivir is safe and appears to be effective when used as treatment or prophylaxis to control outbreaks of influenza in older nursing home residents.
引用
收藏
页码:608 / 616
页数:9
相关论文
共 39 条
[11]  
Ellis E, 1989, Can Dis Wkly Rep, V15, P239
[12]  
GOEVART TM, 1994, JAMA-J AM MED ASSOC, V272, P1661
[13]  
GRAVENSTEIN S, 2000, 40 INT C ANT AG CHEM
[14]   THE EFFICACY OF INFLUENZA VACCINE IN ELDERLY PERSONS - A METAANALYSIS AND REVIEW OF THE LITERATURE [J].
GROSS, PA ;
HERMOGENES, AW ;
SACKS, HS ;
LAU, J ;
LEVANDOWSKI, RA .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (07) :518-527
[15]   Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir [J].
Gubareva, LV ;
Kaiser, L ;
Matrosovich, MN ;
Soo-Hoo, Y ;
Hayden, FG .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (04) :523-531
[16]   Influenza virus neuraminidase inhibitors [J].
Gubareva, LV ;
Kaiser, L ;
Hayden, FG .
LANCET, 2000, 355 (9206) :827-835
[17]   Inhaled zanamivir for the prevention of influenza in families. [J].
Hayden, FG ;
Gubareva, LV ;
Monto, AS ;
Klein, TC ;
Elliott, MJ ;
Hammond, JM ;
Sharp, SJ ;
Ossi, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (18) :1282-1289
[18]   Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza [J].
Hayden, FG ;
Atmar, RL ;
Schilling, M ;
Johnson, C ;
Poretz, D ;
Paar, D ;
Huson, L ;
Ward, P ;
Mills, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) :1336-1343
[19]   Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza - Randomized controlled trials for prevention and treatment [J].
Hayden, FG ;
Treanor, JJ ;
Fritz, RS ;
Lobo, M ;
Betts, RF ;
Miller, M ;
Kinnersley, N ;
Mills, RG ;
Ward, P ;
Straus, SE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (13) :1240-1246
[20]   AMANTADINE-RESISTANT INFLUENZA-A IN NURSING-HOMES - IDENTIFICATION OF A RESISTANT VIRUS PRIOR TO DRUG-USE [J].
HOUCK, P ;
HEMPHILL, M ;
LACROIX, S ;
HIRSH, D ;
COX, N .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (05) :533-537